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Introduction: Nontuberculous mycobacteria are an uncommon cause of septic olecranon bursitis, though
cases have increasingly been described in both immunocompromised and immunocompetent hosts.
Guidelines recommend a combination of surgical resection and antimicrobials for treatment. This case is
the ﬁrst reported case of nontuberculous mycobacterial olecranon bursitis that resolved without medical
or surgical intervention.
Case presentation: A 67-year-old female developed a painless, ﬂuctuant swelling of the olecranon bursa
following blunt trauma to the elbow. Due to persistent bursal swelling, she underwent three separate
therapeutic bursal aspirations, two involving intrabursal steroid injection. After the third aspiration, the
bursa became erythematous and severely swollen, and bursal ﬂuid grew Mycobacterium avium complex.
Triple-drug antimycobacterial therapy was initiated, but discontinued abruptly due to a rash. Surgery
was not performed. The patient was observed off antimicrobials, and gradually clinically improved with
a compressive dressing. By 14 months after initial presentation, clinical exam revealed complete
resolution of the previously erythematous bursal mass.
Discussion: This is the ﬁrst reported case of nontuberculous mycobacterial olecranon bursitis managed
successfully without surgery or antimicrobials. Musculoskeletal nontuberculous mycobacterial
infections are challenging given the lack of clinical data about optimal duration and choice of
antimicrobials or the role of surgery. Additionally, the potential toxicity and drug interactions of
antimycobacterials are not insigniﬁcant and warrant close monitoring if treatment is pursued.
Conclusion: This case raises an important clinical question of whether close observation off
antimicrobials is appropriate in select cases of immunocompetent patients with localized atypical
mycobacterial disease of soft tissue and skeletal structures.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Nontuberculous mycobacteria are ubiquitous in the environ-
ment, yet remain uncommon causes of septic bursitis, with most
cases reported as occurring in immunocompromised hosts.
However, cases of nontuberculous mycobacterial olecranon
bursitis occurring in the immune competent have been described
in the recent past [1–4]. Our review of the literature demonstratesAbbreviations: AFB, acid-fast bacillus; MAC, Mycobacterium avium complex; MRSA,
methicillin-resistant Staphylococcus aureus; M., Mycobacterium; ATS, American
Thoracic Society.
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4.0/).that 42 percent (8 of 19) of reported cases of nontuberculous
mycobacterial olecranon bursitis had some form of immune
compromise, such as immunosuppressive medications or condi-
tions (Table 1). Potential portals of entry of atypical mycobacteria
into the bursa include introduction through bursal aspiration or
steroid injection into an initially inﬂamed, uninfected bursa, or
percutaneous entry through a minor traumatic break in the skin
contaminated by soil or water. An outbreak of atypical mycobac-
terial intramuscular infections was described in China in 1997–
1998, which was traced back to contaminated vial lids for
penicillin injections [5]. The diagnosis of nontuberculous myco-
bacterial bursitis is often delayed, as symptoms tend to be mild and
constitutional symptoms are typically absent. This clinical
presentation often leads to therapeutic modalities for aseptic
bursitis, such as repeated steroid injections, which may exacerbatee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Table 1
Cases of olecranon bursitis caused by nontuberculous mycobacteria.
Age/sex Comorbidities or
risk factors
Steroid Use Organism Antimicrobial
treatment regimen
Duration of
treatment
(months)
Number of
surgical
procedures
Outcome Reference
58/M Colon cancer None speciﬁed M. avium complex Rifampin 1 2 Resolved Kozin and Bishop [4]
49/F MCTD, chronic
corticosteroids
Oral M. avium complex Rifampin, ethambutol,
isoniazid
36 1 Recurrence Kozin and Bishop [4]
57/M Psoriasis,
immunomodulator use
(Alefacept)
None M. avium complex Ciproﬂoxacin, rifampin,
clarithromycin
Not speciﬁed 1 Resolved Prasertsuntarasai et al. [7]
53/M None Oral M. avium complex Rifampin, ethambutol,
azithromycin
8 1 Resolved Garrigues et al. [1]
61/M Type II DM, atrial
ﬁbrillation
Intrabursal M. avium complex Ethambutol,
clarithromycin
Not speciﬁed 1 Resolved Olsen et al. [6]
54/F ESRD, CHF, AS, atrial
ﬁbrillation; 1 year s/p
operative ﬁxation of radial
head fracture
Intrabursal M. avium complex,
MRSA, C. glabrata
Unspeciﬁed multidrug
therapy
Not speciﬁed Not speciﬁed Resolved Olsen et al. [6]
68/F Blunt trauma to elbow in
lake
None M. lacus None 0 1 Resolved Turenne et al. [10]
42/M None speciﬁed None speciﬁed M. szulgai None 0 1 Resolved Marks et al. [11]
66/M Elbow laceration in river None speciﬁed M. marinum Minocycline 6 0 Resolved Saadatmand et al. [9]
24/M Superﬁcial elbow
laceration
Intrabursal M. asiaticum Flucloxacillin Two courses given,
duration not speciﬁed
0 Resolved Dawson et al. [3]
79/M None speciﬁed None speciﬁed M. chelonae Cefazolin 1 1 Resolved Kozin and Bishop [4]
20/F Systemic lupus
erythematosus, chronic
corticosteroids
Oral M. fortuitum (grew from
disseminated nodules)
Doxycycline,
erythromycin, norﬂoxacin
then amikacin and
cefoxitin
11 0 Disseminated
infection, death
Laborde et al. [13]
60/M Type II DM, monoclonal
gammopathy
Intrabursal M. goodii Doxycycline and
ciproﬂoxacin
2½ 1 Resolved Friedman and Sexton [14]
40/M Previous bursal
aspirations, swimmer
None M. gordonae Isoniazid and rifampin 12 0 Resolved Lorber et al. [8]
35/M Rugby player Intrabursal M. gordonae Azithromycin and
moxiﬂoxacin
2½ 1 Resolved Garrigues et al. [1]
59/M Elbow laceration in public
swimming pool
Intrabursal M. kansasii Rifampicin, ethambutol,
isoniazid and
pyrazinamide
6 1 Resolved Barham and Hargreaves [2]
64/M Hepatitis; hit elbow on
ice, previous unsuccessful
bursal excision
Intrabursal M. szulgai Rifampin and ethambutol
pre-op, rifampin,
ethambutol, isoniazid and
erythromycin post-op
18 2 Resolved Maloney et al. [15]
40/M Mountain biker but no
reported elbow trauma
Intrabursal M. terrae Rifampin, ethambutol,
and clarithromycin (latter
changed to azithromycin)
11 1 Resolved Garrigues et al. [1]
71/M DM None M. longobardum Rifampin, ethambutol,
isoniazid, pyrazinamide,
then clarithromycin and
ethambutol
1st regimen, 7; 2nd
regimen, unspeciﬁed
2 Developed recurrent infection
with chronic osteomyelitis
after initial surgery and
treatment for extrapulmonary
TB; resolved after second
debridement and targeted
antimycobacterial therapy
Hong et al. [16]
Abbreviations:M.,mycobacterium; DM, diabetes mellitus; CHF, congestive heart failure; AS, aortic stenosis; MRSA, methicillin-resistant Staphylococcus aureus; C., Candida; TB, tuberculosis; MCTD, mixed connective tissue disease; s/
p, status post.
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Fig. 1. Olecranon bursal swelling at the time of initial presentation, September 2013.
Fig. 2. Left elbow appearance 14 months after initial presentation, November 2014.
S. Working et al. / IDCases 2 (2015) 59–62 61an underlying mycobacterial infection. Among the cases described
of atypical mycobacterial bursitis, the average delay in diagnosis is
more than 6 months [1].
Our review of published cases of nontuberculous mycobacterial
olecranon bursitis suggests that surgical resection of the bursa
with or without antimycobacterial therapy is commonly recom-
mended for deﬁnitive treatment. All reported cases of Mycobacte-
rium avium complex (MAC) olecranon bursitis received bursal
resection plus antimicrobial therapy for deﬁnitive cure [1,4,6,7].
We describe a case of iatrogenic MAC olecranon bursitis in an
immunocompetent 67-year-old female that resolved without
antimicrobials or surgery.
Case presentation
A 67-year-old Caucasian female with a past medical history of
coronary artery disease, generalized anxiety disorder and hypo-
thyroidism developed a ﬂuctuant swelling of the olecranon bursa
following a non-penetrating, mild trauma to the elbow. There was
no associated break in the skin, and no local erythema, pain, or
systemic symptoms. Due to persistent swelling 1 month later, she
sought medical evaluation and underwent bursal aspiration of
serous-appearing ﬂuid followed by injection of ten milligrams of
triamcinolone acetonide into the bursa. No cultures were sent.
Several weeks later she developed recurrent bursal swelling for
which she underwent repeat aspiration and steroid injection of ten
milligrams of triamcinolone acetonide. Bursal ﬂuid analysis from
the second aspiration showed nucleated cell count of 2862 with
18% neutrophils, 66% lymphocytes, 16% monocytes, glucose of
41 mg/dl, total protein of 3.9 g/dl, and no crystals. Routine bacterial
cultures of bursal ﬂuid were negative. Five weeks following the
second aspiration and injection, the patient developed recurrent
symptoms of non-erythematous, painless ﬂuctuant swelling over
the olecranon bursa. A third aspiration of serous ﬂuid was
performed and ﬂuid sent for routine bacterial cultures, which
remained negative. The cell count was 3025 with 7% neutrophils,
61% lymphocytes, 32% monocytes, 490 red blood cells per
microliter, and no crystals. Glucose and protein were not
performed. Subsequent to this third aspiration, the bursal swelling
recurred to its previous, pre-aspiration size within two days, and
the patient developed localized warmth and erythema over the
elbow (Fig. 1). The patient continued to have no constitutional
symptoms. She then underwent a fourth aspiration, and cultures of
bursal ﬂuid grew M. avium complex eleven days later in both
aerobic and anaerobic culture media. This positive bursal ﬂuid
culture prompted referral to infectious diseases clinic in Septem-
ber 2013, at which time her physical exam was noteworthy for a
tennis ball-sized ﬂuctuant, erythematous, nontender, mobile mass
over the left elbow. The growth of MAC in routine bacterial cultures
was initially thought to represent a contaminant, so antimicrobials
were not recommended at the time of initial consultation.
However, repeat diagnostic aspiration with routine bacterial and
AFB cultures of bursal ﬂuid was performed 1 month later to
evaluate for persistence of the organism, and MAC grew a second
time, so was therefore felt to represent a true pathogen. Surgical
resection of the bursa followed by a prolonged course of targeted
antimicrobial therapy was considered, however the need for
surgical management of aseptic and septic olecranon bursitis is an
area of debate, and is typically decided on a case-by-case basis. In
this situation, surgical resection of the bursa was ultimately
deferred due to the lack of systemic illness or prior course of
systemic antibiotic therapy with immobilization, as this is the
standard treatment protocol for suspected septic olecranon
bursitis that is utilized by the treating upper extremity orthopedic
surgeon consulted in this case. Antimicrobial therapy with three-
drug treatment was initiated thrice weekly with azithromycin,ethambutol and rifampin and the patient was referred to
occupational therapy for a compressive dressing and fabrication
of a custom orthosis that limited elbow range of motion. After
three doses of this antibiotic regimen, the patient developed a
diffuse urticarial rash and all medicines were discontinued. By her
8-week follow up visit to infectious diseases clinic, however, the
patient was noted to have clinical improvement with use of a
compressive dressing and splint. She had marked decrease in the
amount of swelling and erythema of the bursa. We decided to
continue to observe the patient off antimicrobials and continue
with local supportive care. Seven months later, the patient
returned for follow up. The erythematous ﬂuctuant bursal mass
noted on initial presentation had nearly resolved. At 14 months
after initial presentation a clinical examination revealed full elbow
range of motion, no pain, and complete resolution of the previously
erythematous bursal mass (Fig. 2).
We suspect that in our case patient, MAC was introduced into
the bursa during one of her repeated bursal aspirations or
injections, since cultures of bursal ﬂuid were negative on two
separate occasions before turning positive and the development of
positive cultures for MAC correlated with a clinical change, with
acutely progressive ﬂuctuant swelling of the bursa and new
localized erythema over the bursa. A number of Mycobacterium
S. Working et al. / IDCases 2 (2015) 59–6262species including M. avium have been demonstrated to grow on
blood agar; Lowenstein–Jensen medium is not necessarily required
to isolate most species [8]. In fact, Drancourt et al. [8] found the use
of blood agar to be more cost-effective and perform as well or
better than reference culture broth for the isolation of most
Mycobacterium species.
There are no current standardized guidelines for management
of atypical mycobacterial olecranon bursitis. Our review of
reported cases demonstrated that bursal resection with or without
antimycobacterial therapy is commonly recommended for deﬁni-
tive treatment, and all described instances of cured MAC olecranon
bursitis received bursal resection as well as antimicrobials
[1,4,6,7]. One case of olecranon bursitis described by Olsen et al.
did not specify whether surgery was performed, but this case may
not be entirely applicable as the infection was polymicrobial, with
cultures positive for methicillin-resistant Staphylococcus aureus
(MRSA), Candida glabrata, and MAC, so as such it is unclear if MAC
was truly a pathogen. Cure was attained in two cases with
antimicrobial therapy alone, including one case of Mycobacterium
gordonae infection that was treated with 12 months of isoniazid
plus rifampin, but this diagnosis was made fairly early in the
disease course, there was no underlying immune compromise, and
intrabursal steroid injections were never administered [9]. The
second case involved Mycobacterium marinum infection after a
laceration to the elbow in a river, which resolved with 6 months of
minocycline [10]. Again, there was no form of systemic immune
compromise and no mention of intrabursal steroid injections in
this case. One case each of Mycobacterium lacus and Mycobacterium
szulgai olecranon bursitis have been described as resolving with
surgery alone [11,12]. Dawson et al. [3] reported one case of
probable Mycobacterium asiaticum olecranon bursitis occurring in a
young, healthy male that resolved with povidone-iodine and
hydrogen peroxide dressings to an open, draining bursa without
antimycobacterial therapy or surgery, but the microbiologic
diagnosis was not certain in this case, as M. asiaticum was isolated
in low numbers in only one bursal ﬂuid culture, with failure of the
organism to grow on repeat mycobacterial cultures 8 weeks later.
It is unclear whether antimicrobials are needed after surgical
resection, and if so, for what duration of time. The total duration of
antimicrobials given to the patients in our review varied widely,
rangingfrom1to36months,evenifsurgicalresectionwasperformed.
It has been suggested by Garrigues et al. [1] that greater than 1 year of
therapy is likely not necessary, and shorter courses of antibiotics or no
antibiotics may be reasonable if bursal resection has been performed.
The American Thoracic Society (ATS) guideline provides guidance on
choices and duration of antimicrobials for nontuberculous mycobac-
terial skin, soft tissue, and skeletal disease, but notes that optimal
antimicrobial regimens and duration of treatment have not been
established for most species [13]. For extrapulmonary, localized MAC
disease involving skeletal structures such as tendons and joints, the
ATS recommends 6–12 months of triple-drug therapy, usually
combined with surgical debridement [13].
Upon analyzing published cases of nontuberculous mycobacte-
rial olecranon bursitis and suggested guidelines, it is evident that our
patient’s clinical course and management is unusual in that no other
published cases exist of nontuberculous mycobacterial olecranon
bursitis that resolved without antimicrobials or surgical resection.
Our patient did receive three doses of antimycobacterial therapy, but
this duration of therapy is unlikely to have led to any signiﬁcant
microbiologic cure, since MAC infections across all body sites
typically require multiple months to a year or more of treatment for
cure. Additionally, there was no observed clinical change in the
erythema, swelling or warmth of our patient’s bursa after this
1-week period of treatment; the bursal erythema and swelling did
not subside until 6–7 weeks later. This timeline suggests this
minimal exposure to antimicrobials had no appreciable impact onher clinical outcome. The reasons for our patient’s apparent
resolution of infection remain unclear, but may relate to compres-
sion provided by the pressure dressings and splint, with resorption of
bursal ﬂuid and gradual spontaneous mycobacterial death over time.
Discussion
We report this case of a clinically resolved MAC olecranon bursitis
in order to illustrate that a strategy of close observation off
antimicrobial therapy without surgical intervention may be
worthwhile to consider in select cases of localized nontuberculous
mycobacterial infections of soft tissue and certain skeletal struc-
tures. Such cases may include those who are not surgical candidates,
patients who cannot tolerate multi-drug antibiotic therapy, and/or
those in whom the risk of drug–drug interactions precludes the
use of antimycobacterial agents. However, we do not recommend
this treatment option in the immunocompromised host.
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